Intellia Therapeutics, Inc.

Intellia Therapeutics (NTLA) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, the absence of recent events does not eliminate execution risk—CRISPR-focused biotech companies face inherent clinical, regulatory, and capital intensity challenges that require deeper analysis. Our 90-day window captures only recent noise; the full $49 Report extends coverage to 12 months, layers in dilution risk scoring, financing history, and AI-detected risk signals across SEC filings. The full $49 Report adds comprehensive capital structure analysis, forward dilution exposure, and pattern detection across the complete filing history.